NOTCH signaling in skeletal progenitors is critical for fracture repair by Wang, Cuicui et al.
















See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Wang, Cuicui; Inzana, Jason A.; Mirando, Anthony J.; Ren, Yinshi; Liu, Zhaoyang; Shen, Jie; O'Keefe, Regis J.; Awad, Hani A.; and




Cuicui Wang, Jason A. Inzana, Anthony J. Mirando, Yinshi Ren, Zhaoyang Liu, Jie Shen, Regis J. O'Keefe,
Hani A. Awad, and Matthew J. Hilton
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/4883
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
1 4 7 1jci.org   Volume 126   Number 4   April 2016
Introduction
Although most fractures progress to union, 10% to 20% result in 
nonunions and are often associated with morbidity, prolonged 
hospitalization, and increased expenses (1–3). Risk factors for 
fracture nonunion can include malnutrition, infection, metabolic 
disease, poor vascularization or vascular disease, fracture com-
minution, and most commonly, inappropriate fixation or stabiliza-
tion at the fracture site (4). However, there remain questions as to 
whether systemic factors or impaired cellular function may play a 
role in the pathogenesis of fracture nonunion, particularly in cases 
that do not heal after appropriate surgical intervention. A reduced 
pool of human bone marrow stromal/stem cells (BMSCs) corre-
lates with altered bone repair in patients with fracture nonunions 
(5, 6). The administration of BMSCs has shown promise in treating 
patients with fracture nonunions in some settings (7–12). Interest-
ingly, recent studies using reporter-tagged BMSCs have demon-
strated that transplanted BMSCs specifically localize within the 
fracture gap and intramedullary or internal calluses rather than 
within the external callus tissues mostly derived from the perios-
teum and surrounding soft tissue, suggesting a localized and spe-
cific role for BMSCs in fracture repair (13, 14). While the impor-
tance of BMSC-associated osteogenesis during development has 
been established, the functional role and importance of BMSCs in 
fracture healing remain to be determined.
Through the use of mouse genetic studies, we and others have 
demonstrated that loss of NOTCH signaling in skeletal progeni-
tors leads to an early increase in bone mass, depletion of the BMSC 
pool, and subsequent age-related bone loss (15, 16). The NOTCH 
signaling pathway is a known regulator of various stem cell popula-
tions that signals via single-pass transmembrane ligands (JAG1/2 
and DLL1/3/4) and receptors (NOTCH1/4), culminating in the 
activation of a transcriptional complex composed of the NOTCH 
intracellular domain (NICD), the mastermind-like transcriptional 
coactivator (MAML), and the central regulator known as recombi-
nation binding protein for immunoglobulin kappa J region (RBPjκ) 
(17). Although NOTCH signaling is critical for maintaining BMSCs 
during skeletal development (15, 16), little evidence exists for a par-
ticular role for NOTCH signaling during fracture repair. Here, we 
set out to test the hypothesis that NOTCH signaling in skeletal pro-
genitors serves to preserve the numbers and maintain the progeni-
tor status of BMSC populations that are critical for normal fracture 
repair and unification, while NOTCH signaling within more com-
mitted skeletal lineages may be largely dispensable.
Fracture nonunions develop in 10%–20% of patients with fractures, resulting in prolonged disability. Current data suggest 
that bone union during fracture repair is achieved via proliferation and differentiation of skeletal progenitors within periosteal 
and soft tissues surrounding bone, while bone marrow stromal/stem cells (BMSCs) and other skeletal progenitors may also 
contribute. The NOTCH signaling pathway is a critical maintenance factor for BMSCs during skeletal development, although 
the precise role for NOTCH and the requisite nature of BMSCs following fracture is unknown. Here, we evaluated whether 
NOTCH and/or BMSCs are required for fracture repair by performing nonstabilized and stabilized fractures on NOTCH-
deficient mice with targeted deletion of RBPjk in skeletal progenitors, maturing osteoblasts, and committed chondrocytes. 
We determined that removal of NOTCH signaling in BMSCs and subsequent depletion of this population result in fracture 
nonunion, as the fracture repair process was normal in animals harboring either osteoblast- or chondrocyte-specific deletion 
of RBPjk. Together, this work provides a genetic model of a fracture nonunion and demonstrates the requirement for NOTCH 
and BMSCs in fracture repair, irrespective of fracture stability and vascularity.
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cortices at 14 dpf that remained evident up to and beyond 42 dpf 
(Figure 1B). Reconstruction of μCT data revealed that mineral-
ized callus volumes in WT fractures peaked at 14 dpf and rapidly 
decreased from 14 dpf to 42 dpf, suggesting continuous external 
callus remodeling. Quantitatively, substantial new external cal-
lus bone formation was observed in RBPjκPrx1 mutant fractures, 
reflecting relatively normal and robust periosteal and soft tissue 
responses in these mutants. In contrast, bone remodeling was 
likely delayed in RBPjκPrx1 mutant fractures, since callus volumes 
did not show a decline until beyond 28 dpf (Figure 1C).
A fibrous hypertrophic nonunion develops in RBPjκPrx1 mutant 
fractures. Histological assessments of fracture repair were per-
formed using alcian blue/hematoxylin/orange-g (ABH/OG) stain-
ing of RBPjκPrx1 mutant and WT fracture calluses at 7, 14, 28, and 
42 dpf (Figure 2A). At 7 dpf, WT and RBPjκPrx1 mutant fracture 
calluses were comparable, with early signs of mesenchymal cell 
recruitment, cartilage formation in the external calluses, and the 
appearance of vascular tissue noted by the presence of red blood 
cells (Figure 2A). By 14 dpf, further callus formation in WT frac-
tures was observed in 3 areas, including (a) the endosteal surface 
close to the fracture rim and within the intramedullary BM space, 
(b) the fracture gap directly adjacent to the fractured cortices, and 
(c) the periosteal surface of both proximal and distal sides of the 
tibiae, where the transition from cartilaginous to bony callus was 
nearly complete. By 28 dpf, the cortices in WT fractures were uni-
fied by bridging calluses in both the periosteal and intramedullary 
areas. Due to bony union and new bone remodeling, WT fractures 
were completely repaired, as illustrated by the restoration of the 
original lamellar structure of the cortical bone by 42 dpf (Figure 
2A). Alternatively at 14 dpf, RBPjκPrx1 mutants exhibited no internal 
callus formation, but rather displayed a persistence of undifferen-
tiated mesenchymal tissue within both the intramedullary space 
and the fracture gap. Interestingly, relatively normal external cal-
lus formation could be visualized along the periosteal surfaces, 
although the replacement of cartilage by bone was delayed, sug-
gesting the periosteal-derived stem/progenitor cell (PSC) popu-
Results
Loss of NOTCH signaling in skeletal progenitors results in fracture 
nonunion. To examine the role of NOTCH signaling during frac-
ture repair, we generated a loss-of-function (LOF) mouse model 
in which floxed alleles for the transcriptional NOTCH effector 
RBPjκ were conditionally deleted in skeletal progenitors. West-
ern blot analyses confirmed that RBPjκ was efficiently deleted 
in the skeletal lineages of Prx1-Cre RBPjkfl/fl (herein referred to as 
RBPjκPrx1) mice at 2 months of age (Supplemental Figure 1; supple-
mental material available online with this article; doi:10.1172/
JCI80672DS1). To identify the cell lineages targeted by Prx1-Cre 
and contribute to callus formation during fracture repair, we ana-
lyzed tibia fractures on Prx1-Cre R26RLacZ mice at 14 days post 
fracture (dpf). X-gal staining on fracture calluses revealed LacZ-
positive cells in the periosteum, the BM of the diaphysis, and both 
the external and internal cartilaginous and bony callus (Supple-
mental Figure 2). These data demonstrate that all skeletal-related 
cells in the callus are derived from Prx1-expressing progenitors, 
which largely reside in both the periosteum and BM.
To determine whether normal fracture repair requires a 
NOTCH-maintained population of BMSCs, we performed non-
stabilized tibia fractures on RBPjκPrx1 (largely depleted of the clo-
nogenic fraction of BMSCs) and WT control mice at 2 months of 
age. Radiographs of WT fractures demonstrated the initial signs of 
external callus forming by 14 dpf, followed by the disappearance 
of the cortical gap via a bridging internal and external bony cal-
lus by 28 dpf, indicating fracture unification. In contrast, RBPjκPrx1 
mutant fractures showed prominent callus formation along the 
periosteum extending away from the fracture line at 14 and 28 dpf; 
however, no bridging callus between the cortices was observed. 
Radiographic observations out to 42 dpf demonstrated a clear 
nonunion of RBPjκPrx1 mutant tibiae (Figure 1A). Consistent with 
radiographic data, μCT analyses on mineralized calluses of WT 
fractures showed a nearly complete bridging of bony calluses by 14 
dpf, followed by complete bridging at 28 dpf and beyond. RBPjκPrx1 
fractures presented with a large radiolucent space between broken 
Figure 1. Loss of NOTCH signaling in MSCs results in fracture nonunion. (A) A real-time radiographic comparison of 2 representative nonstabilized tibia 
fractures from WT and RBPjκPrx1 mutant mice at 0, 14, 28, and 42 dpf revealed persistent fracture lines (yellow arrows) at 42 dpf, suggesting an established 
fracture nonunion in RBPjκPrx1 mutants. n = 12 mice per genotype per time point. (B) μCT analyses of 14-, 28-, and 42-day-old WT and RBPjκPrx1 mutant 
fractures revealed substantial periosteal external callus formation by 14 dpf and beyond, but apparent radiolucent space (yellow arrows) between broken 
cortices at 42 dpf in RBPjκPrx1 mutants. n = 7 mice per genotype per time point. (C) Reconstruction of μCT data reflected the normal and robust periosteal 
response in RBPjκPrx1 mutants; however, the new bone remodeling was delayed in these animals. n = 7 mice per genotype per time point. *P < 0.05 com-
pared with WT by 2-way ANOVA followed by Dunnett’s post hoc test. Results are expressed as mean ± SD.
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tures mostly appeared within the internal or intramedullary callus 
area and ultimately caused the lack of any bone unification (Figure 
3A). To determine the structural impact of the altered fracture-
healing processes, we analyzed fractured WT and RBPjκPrx1 mutant 
tibiae at 42 dpf using biomechanical torsion testing. As expected, 
all biomechanical parameters, including bone strength, bone 
stiffness, and bone toughness, were markedly lower in RBPjκPrx1 
mutant tibiae (~7-fold lower, P ≤ 0.002) (Figure 3B). No failure 
moment could be specifically detected in RBPjκPrx1 mutant tibiae, 
indicating the complete absence of any rigid unifying structure 
(Figure 3B). In addition, the minimal torsional stiffness possessed 
by RBPjκPrx1 mutant fractured tibiae suggested soft tissue bridging 
of bone fragments, resulting in a slow tearing rather than abrupt 
breaking during tests (Figure 3B). The fully restored mechanical 
competence in the WT group, compared with nearly undetectable 
parameters in the mutant group, demonstrated not just delayed 
fracture repair, but rather an actual and complete nonunion.
The fracture nonunions observed in RBPjκPrx1 mutants are likely 
due to the depleted and/or defective BMSC pool, rather than altered 
vascularization or osteoclast numbers. To determine whether 
alterations in vascularization contribute to fracture nonunions in 
RBPjκPrx1 mutants, we performed PECAM immunofluorescence 
(IF) on callus sections at 14 dpf. In regions of the external callus, 
we observed similar patterns of vascularization between WT and 
mutant fractures. The cartilaginous tissue was avascular, and 
new blood vessels invaded areas of new bone formation, indicat-
ing normal endochondral bone healing within external calluses 
from both groups (Supplemental Figure 3, B and E). Within areas 
of internal calluses of WT fractures, we also observed that bone 
fragments were bridged by avascular cartilaginous tissue flanked 
by vascular tissue (Supplemental Figure 3, A and C). Surprisingly, 
abundant PECAM expression was observed across the fracture 
gap containing mesenchymal-like fibrous tissue without evidence 
of bone formation in RBPjκPrx1 mutants (Supplemental Figure 3, D 
and F). Thus, it was unlikely that the fracture nonunions observed 
in RBPjκPrx1 mutants could be attributed to a disrupted vascular net-
work, since the tissues within the fracture gap were highly vascu-
larized. Vascularization at all stages of fracture repair was further 
evidenced by the presence of red blood cells and vascular tissues 
within the intramedullary and fibrous tissue domains observed 
within the ABH/OG-stained histology sections from the RBPjκPrx1 
mutant fractures (Figure 2A). Additionally, tartrate resistant acid 
phosphatase (TRAP) staining for osteoclasts was also assessed 
to determine whether dysregulated osteoclastogenesis could be 
lation was largely unaffected in RBPjκPrx1 mutant mice. By 28 dpf 
and beyond, regions of the intramedullary space and fracture 
gap mostly were filled with mesenchymal fibrous tissue (Figure 
2A). To determine the fibrotic nature of the mesenchymal tissue 
that developed and persisted at the fracture site, we performed 
immuno histochemistry (IHC) for COL3A1 (Figure 2B). COL3A1 
expression, which was minimally visualized in WT fracture sec-
tions at 14 dpf, dissipated over time, as it does during normal 
fracture repair. Alternatively, COL3A1 appeared to be more pro-
nounced over the course of healing in RBPjκPrx1 mutant fracture 
sections, especially within the fracture gap and the intramedullary 
mesenchymal area, confirming that a fibrous nonunion developed 
in these mutant mice (Figure 2B).
We next performed quantitative assessments of tissue compo-
sition of fracture calluses to further understand fracture healing 
in these mice. Consistent with histological observations, histo-
morphometric results revealed that the cartilage and bone areas 
were significantly increased in RBPjκPrx1 mutant fractures through-
out much of the fracture repair process, which was attributed to 
the robust endochondral bone formation that occurred along the 
periosteal surfaces as well as the delayed bone remodeling (Fig-
ure 3A). The significantly greater amount of mesenchymal tissue 
observed throughout the healing process in RBPjκPrx1 mutant frac-
Figure 2. Loss of NOTCH signaling in MSCs results in histological changes 
consistent with the pathology of fracture nonunion. (A) ABH/OG-stained 
callus sections from WT and RBPjκPrx1 mutants at 7, 14, 28, and 42 dpf 
showed prominent external callus formation (blue dotted line area) and 
persistent mesenchymal tissue (yellow dotted line area) within the internal 
callus area, which was ultimately filled with mesenchymal fibrous tissue 
(green arrows) in RBPjκPrx1 mutant fractures. Mesenchymal/fibrotic callus 
regions are shown at high magnification in blue boxes. n = 5 mice per 
genotype per time point. (B) IHC for COL3A1 on callus sections from WT and 
RBPjκPrx1 mutant fractures at 14, 28, and 42 dpf confirmed the formation of 
mesenchymal-like fibrous tissue in the fracture gap of RBPjκPrx1 mutants. 
n = 5 mice per genotype per time point. Original magnification, ×5. Red 
arrows indicate the expression of COL3A1.
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from 2-month-old WT C57BL6/J mice treated with either 10 μM 
N-[(3,5-difluorophenyl)acetyl]-l-alanyl-2-phenyl]glycine-1,1-di-
methylethyl ester (DAPT) (Calbiochem), a γ-secretase inhibitor 
that inhibits all NOTCH signaling, or DMSO as a control. Crystal 
violet staining of BMSC cultures with continuous NOTCH inhibi-
tion from days 3 to 17 after plating showed a dramatic reduction 
in type I CFU-Fs compared with that in DMSO-treated controls 
(Figure 4, C and D). Gene-expression analyses from these cul-
tures demonstrated direct NOTCH inhibition in BMSCs via the 
downregulation of the NOTCH target gene hairy and enhancer of 
split 1 (Hes1) (Figure 4E). DAPT treatments subsequently resulted 
in a dramatic downregulation of leptin receptor (Lepr) expression 
(Figure 4E), which marks a critical subset of clonogenic BMSCs 
specifically derived from the intramedullary and endocortical 
BM and serves as an important skeletal progenitor source that 
contributes to normal fracture repair (18). Consistent with this 
reduction of skeletal progenitors or early osteogenic cells follow-
ing 2 weeks of DAPT treatments, we observed a decrease in col-
lagen type I alpha 1 (Col1a1) expression and a subsequent increase 
in Alp and osteocalcin (Oc) expression, suggesting that remaining 
cells were a more committed osteogenic cell population (Figure 
4E). Collectively, these data argue that NOTCH signaling inhi-
bition directly within skeletal progenitors results in a significant 
effect on BMSC populations, such that they lose their progenitor 
status with time and that, following fracture, RBPjκPrx1 mutants 
likely form fibrous nonunions due to the depletion of BMSC pop-
ulations with altered differentiation potential.
Loss of NOTCH signaling in osteoblasts or chondrocytes does 
not result in fracture nonunion. Thus far, we could not rule out the 
possibility that NOTCH-defective osteoblasts or chondrocytes 
contribute significantly to the nonunion phenotype observed in 
RBPjκPrx1 mutant fractures, since the Prx1-Cre lineage traces to 
more committed osteoblast and chondrocyte populations during 
fracture repair (Supplemental Figure 2). Therefore, to determine 
whether loss of NOTCH signaling in osteoblasts could also lead 
to fracture nonunion, we first traced the fate of Col1a1(2.3 kb)–
expressing osteoblastic cells during fracture repair by analyzing 
the fracture callus of Col1a1-Cre(2.3 kb) R26RLacZ mice at 14 dpf. 
X-gal staining revealed LacZ-positive cells in the cambium layer 
of the periosteum, but not in the BM (Supplemental Figure 5, D 
and F). Furthermore, we observed a large number of LacZ-pos-
itive cells in the external callus, in particular, in regions of hard 
an underlying contributor to fracture nonunion. While the total 
number of TRAP-positive cells observed throughout mutant frac-
ture sections was greater than that in WT controls (Supplemental 
Figure 4A), the percentage of bone surface covered by osteoclasts 
(OC.S./B.S.) was comparable or lower (Supplemental Figure 4B). 
Therefore, these data indicate that the fracture nonunions in 
RBPjκPrx1 mutants are not caused by enhanced osteoclastogenesis.
Previous studies have demonstrated that loss of NOTCH 
signaling in skeletal progenitors significantly enhanced trabecu-
lar bone mass in adolescent mice at the expense of depleting the 
BMSC or skeletal progenitor pool (15, 16). We reasoned that the 
fracture nonunion observed in RBPjκPrx1 mutants might be due to 
this significant reduction in BMSCs. Since skeletal progenitors 
are found in the clonogenic subset of adherent BM-associated 
cells identified by CFU assays, we isolated cells from WT and 
RBPjκPrx1 mutant fractures at 42 dpf and assayed for CFU-fibro-
blastic (CFU-F) and CFU-osteoblastic (CFU-OB) frequency in 
BM-associated cells. Crystal violet staining of CFU-Fs and alka-
line phosphatase (ALP) staining of CFU-OBs revealed remarkably 
fewer type Ι CFU-Fs and CFU-OBs in the BM of RBPjκPrx1 mutant 
fractures (Figure 4, A and B), indicating a severe diminution of 
the clonogenic fraction of the BMSC pool. Interestingly, the ratio 
of CFU-OB to CFU-F was significantly higher in the BMSC cul-
tures from RBPjκPrx1 mutant fractures (Figure 4B), suggesting the 
remaining clonogenic BMSCs were less “stem-like” and more 
differentiated than those present in WT fractures. To determine 
the direct impact of NOTCH inhibition on clonogenic subsets 
of BMSCs, we performed CFU-F assays using BMSCs isolated 
Figure 3. RBPjκPrx1 mutant fractures have altered callus composition with 
remarkably inferior biomechanical properties. (A) Histomorphometric 
quantifications of the cartilage, bone, and mesenchymal areas (Ar.) from 
ABH/OG-stained sections show robust cartilage and bone formation in 
the external callus regions and the progression of fracture nonunion in 
RBPjκPrx1 mutant fractures. n = 5 mice per genotype per time point. *P 
< 0.05 compared with WT by 2-way ANOVA followed by Dunnett’s post 
hoc test. Results are expressed as mean ± SD. (B) Biomechanical torsion 
testing of WT and RBPjκPrx1 mutant fractures at 42 dpf. All biomechanical 
parameters, including the maximum torque, torsional rigidity, and energy 
to maximum, which represent the bone strength, bone stiffness, and 
bone toughness, respectively, were markedly lower in RBPjκPrx1 mutant 
repaired tibia than those in the WT controls. n = 7 mice per genotype. *P < 
0.05 compared with WT by 2-tailed, unpaired Student’s t test. Results are 
expressed as mean ± SD.
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CreERT2 RBPjkfl/fl (hereafter RBPjκAcanTM) and WT control mice at 2 
months of age. RBPjκAcanTM and WT mice received TM (1 mg/10 
g body weight) via intraperitoneal injections at 3, 5, 7, and 9 dpf 
to induce recombination of RBPjk floxed alleles following initia-
tion of fracture repair during the chondrogenic or endochondral 
phase. Radiographs showed the initiation of mineralized cal-
lus at 14 dpf and complete bridging and bony union in both WT 
and RBPjκAcanTM mutant mice by 28 dpf (Figure 6A). IHC analyses 
from WT and RBPjκAcanTM fracture calluses at 10 dpf during the 
endochondral phase confirmed an extremely efficient removal 
of RBPjκ specifically from within chondrocytes and not adjacent 
mesenchymal/osteogenic tissue (Figure 6B). Histological analy-
ses at both 10 and 28 dpf further confirmed the radiographic 
results and demonstrated that RBPjκAcanTM mutant mice undergo 
normal fracture repair processes with timely bony union (Figure 
6B). Collectively, these data demonstrate that NOTCH signaling 
is dispensable in the differentiated cell lineages of osteoblasts or 
chondrocytes during fracture repair, while NOTCH signaling in 
the earliest skeletal progenitors is absolutely required for normal 
bone healing and unification.
Insufficient fracture stabilization is not required for fracture non-
union observed in RBPjκPrx1 mutants. To exclude the possibility that 
fracture nonunion observed in RBPjκPrx1 mutants was promoted by 
insufficient stabilization, we employed a rigidly stabilized femur 
osteotomy model. Two different gap sizes (1.2 mm and 0.66 mm) 
calluses. In contrast, no LacZ-positive cells were detected within 
the developing internal callus (Supplemental Figure 5, H and J). 
These results indicate that Col1a1(2.3 kb)–expressing osteoblasts 
in the periosteum only contribute to the formation of the exter-
nal callus, but not the internal callus. We next analyzed fractures 
from mice with NOTCH signaling selectively removed from 
osteoblasts using the Col1a1-Cre(2.3 kb) transgenic line (Col1a1-
Cre(2.3 kb); RBPjkfl/fl, hereafter RBPjκCol1). Western blot analyses 
confirmed that RBPjκ was efficiently deleted in osteoblasts of 
RBPjκCol1 mice (Supplemental Figure 6). We then performed non-
stabilized tibia fractures on RBPjκCol1 or RBPjkfl/fl (WT control) 
mice. No significant differences in fracture repair between the 
2 groups were revealed by any of the analyses, including radio-
graphic, μCT, histological, and histomorphometric assessments 
(Figure 5). We also detected comparable CFU-Fs and CFU-OBs 
in the BM from RBPjκCol1 mutant fractures and controls at 42 dpf, 
indicating that the BMSCs in RBPjκCol1 mutants were unaffected 
by loss of NOTCH signaling in maturing osteoblasts (Supplemen-
tal Figure 7). These data demonstrate that RBPjκCol1 mutant mice, 
in which NOTCH signaling is selectively removed in mature 
osteoblasts, are capable of normal fracture repair.
To determine whether loss of NOTCH signaling in fracture 
callus chondrocytes could also lead to fracture nonunion similar 
to that observed in RBPjκPrx1 mutants, we performed nonstabilized 
tibia fractures on tamoxifen-inducible (TM-inducible) Acan-
Figure 4. Fracture nonunions observed in 
RBPjκPrx1 mutants are likely due to the signifi-
cant reduction of BMSC numbers and altered 
differentiation status. (A) CFU-F assays on 
BMSCs isolated from WT and RBPjκPrx1 mutant 
fractures at 42 dpf. Representative images 
for crystal violet staining of CFU-Fs and ALP 
staining of CFU-OBs are both shown. (B) 
RBPjκPrx1 mutant fractures are associated with 
significantly reduced type 1 colonies (CFU-Fs) 
and ALP-positive colonies (CFU-OBs), but an 
increased ratio of CFU-OB to CFU-F. n = 6 mice 
per genotype. *P < 0.05 compared with WT by 
2-tailed, unpaired Student’s t test. Results are 
expressed as mean ± SD. (C) CFU-F assays for 
BMSCs isolated from WT mice at 2 months of 
age and treated with either DMSO or DAPT for 
14 days beginning on their third day in culture. 
Representative images for crystal violet stain-
ing of CFU-Fs are shown. (D) Quantification of 
DMSO- and DAPT-treated BMSC cultures show 
significantly reduced type 1 colonies (CFU-Fs). 
*P < 0.05 compared with DMSO control by 
2-tailed, unpaired Student’s t test. Results 
are expressed as mean ± SD of 4 independent 
experiments. (E) Relative gene expression for 
Hes1, Lepr, Col1a1, Alp, and Oc in DAPT-treated 
BMSCs as compared with DMSO-treated con-
trol. *P < 0.05, compared with DMSO control 
by 2-tailed, unpaired Student’s t test. Results 
are expressed as mean ± SD of 3 independent 
experiments.
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of osteotomy were created in femurs of RBPjκPrx1 mutants and 
WT controls and stabilized with a rigid internal fixator. By 14 dpf, 
radiographs revealed complete periosteal bridging in the control 
mice with a 1.2-mm osteotomy. In contrast, although the osteoto-
my gap narrowed and obscured on radiographs, radiolucent space 
could still be observed at 42 dpf in RBPjκPrx1 mutant femurs (Figure 
7A). Three-dimensional reconstructed μCT images also demon-
strate impaired healing and nonunion in RBPjκPrx1 mutant femurs 
(Figure 7B). Quantitatively, the bony callus within the 1.2-mm 
defect, representing the volume of the internal callus, was signifi-
cantly lower in the RBPjκPrx1 mutants. The values of the minimum 
polar moment of inertia (PMOI) (0.76 mm4) were significantly less 
than those of controls (4.60 mm4), indicating a lack of bone union 
and a high propensity of failure (Figure 7, C and D). Histologi-
cally, at 42 dpf, the 1.2-mm WT osteotomies exhibited complete 
continuity of the cortex with mature lamellar structure and nor-
mal BM, whereas no healing was evident in RBPjκPrx1 mutants. In 
place of normal healing, RBPjκPrx1 mutant osteotomies developed 
a cap-like structure sealing the medullary canal. Often, one seg-
ment would have some mineralization and bone formation near 
the osteotomy site, while the other was occupied by loose, fibrous 
tissue (Figure 7E). IHC for COL3A1 on 42 dpf mutant osteotomy 
sections further confirmed the fibrotic nature of the tissue within 
the osteotomy gap (Figure 7E).
For the 0.66-mm osteotomies, autoradiographs indicated 
bony bridging in the control group at 14 dpf; however, by 21 dpf, 
the RBPjκPrx1 mutants still exhibited a radiolucent area at the level 
of the osteotomy (Supplemental Figure 8A). μCT scanning showed 
the same pattern of defective repair as observed in the autoradio-
graphs (Supplemental Figure 8B). Histological analysis at 21 dpf 
demonstrated that new mineral deposition bridged the osteotomy 
gap, and islands of disorganized bone formed in the marrow space 
of WT controls. Alternatively, by 21 dpf, only one side of the bone 
fragments displayed bridging in RBPjκPrx1 mutants, with small 
islands of mineralized trabecular bone in the intramedullary cav-
ity. The opposing cortical bone did not show signs of healing or 
callus formation (Supplemental Figure 8C), indicating that the 
mutant osteotomy resulted in incomplete and inappropriate bridg-
ing. Therefore, osteotomies in RBPjκPrx1 mutants developed either 
incomplete unions or nonunions, suggesting that insufficient sta-
bilization is not required for fracture nonunion to occur, although 
defect size may contribute to the healing outcome.
Discussion
NOTCH signaling is a recently established pathway critical to 
skeletal development and disease in both mice (15, 16, 19–25) 
and humans (26–28). Fracture-repair mechanisms are believed 
to recapitulate a series of spatiotemporal cellular and signaling 
events that occur during skeletal development (29, 30), suggesting 
a potential involvement of NOTCH signaling. Evidence that fur-
ther implicates NOTCH in the general processes of fracture repair 
has recently emerged, including: (a) an upregulation of some 
NOTCH components in murine callus tissues during fracture 
healing (31), (b) a downregulation of NOTCH signaling specifi-
Figure 5. Loss of NOTCH signaling in mature 
osteoblasts does not lead to fracture 
nonunion. (A) A real-time radiographic 
comparison of 2 representative nonstabi-
lized tibia fractures from WT and RBPjκCol1 
mutant mice at 0, 14, 28, and 42 dpf revealed 
normal fracture repair in RBPjκCol1 mutants. 
n = 7 mice per genotype. (B) Representative 
μCT images of fracture calluses from WT and 
RBPjκCol1 mutants at 42 dpf. n = 7 mice per 
genotype. *P < 0.05 compared with WT by 
2-tailed, unpaired Student’s t test. Results 
are expressed as mean ± SD. (C) Reconstruc-
tion of μCT data revealed a similar amount of 
mineralized calluses between WT and RBPjκCol1 
mutants at 42 dpf. (D) ABH/OG-stained callus 
sections from RBPjκCol1 mutants and controls 
at 42 dpf. Original magnification, ×2.5. (E and 
F) Histomorphometric analyses of ABH/OG-
stained callus sections indicated no significant 
differences in bone and mesenchyme area 
between WT and RBPjκCol1 mutant fractures. 
n = 7 mice per genotype. *P < 0.05 compared 
with WT by 2-tailed, unpaired Student’s t test. 
Results are expressed as mean ± SD.
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cally within certain mouse skeletal progenitors during early frac-
ture repair (32), and (c) evidence that systemic downregulation of 
NOTCH signaling just prior to fracture prolongs the inflammatory 
phase and alters fracture healing in mice (33). While these studies 
have implicated NOTCH in the fracture-repair process, the precise 
role of NOTCH within specific cell lineages remained unknown. 
Our findings here provide what we believe is the first genetic evi-
dence that NOTCH signaling removal specifically within skeletal 
progenitors results in clonogenic BMSC depletion and fracture 
nonunion, while NOTCH removal in maturing osteoblasts and 
chondrocytes leads to no impairment in fracture healing and bone 
unification (34, 35). Our use of multiple fracture modalities and 
multiple gene targeting approaches has proven the requisite role 
for BMSCs and NOTCH signaling within BMSCs during fracture 
repair, irrespective of fracture stability and vascularization. Col-
lectively, our work implicates both defective NOTCH signaling 
and BMSCs as possible causes of the failed or inappropriate intra-
medullary callus formation leading to fracture nonunions.
Current dogma suggests that various skeletal progenitors are 
recruited to the fracture site during bone repair, with at least 2 
likely participants being BMSCs and PSCs (36, 37). Fracture cal-
lus development is known to occur at 3 specific loci: the medul-
lary canal, the area between fractured cortices, and the extramed-
ullary space, including the subperiosteal layer and surrounding 
soft tissues (13, 14). However, the precise identity of cells con-
tributing to callus development and their relative contribution 
are not well defined. It is difficult to distinguish the precise role 
of various skeletal progenitors during fracture repair, partly due 
to the complex nature of the fracture-healing process, but also 
due to the lack of specific progenitor markers. Thus far, studies 
assessing the contribution of progenitor sources to bone healing 
have largely relied on transplantation approaches (13, 14, 38–41). 
In vivo lineage analyses using transplanted live bone grafts have 
demonstrated that the periosteum supports endochondral ossi-
fication, while BM/endosteum supports intramembranous ossi-
fication during bone repair (40). Periosteal progenitors give rise 
solely to skeletal cells specifically localized within the develop-
ing external callus (39, 40). Alternatively, reporter-tagged BM/
BMSC transplantations have demonstrated that BMSCs localize 
to the fracture gap and may contribute to intramedullary or inter-
nal callus formation (13, 14). Based on these and other findings, 
we speculate that skeletal progenitors derived from the perios-
teum and BM/endosteum contribute differently to bone healing. 
While PSCs establish the external callus to provide rapid stability 
to the fracture via endochondral ossification, BMSCs might act 
to form the internal callus via intramembranous ossification and 
contribute markedly to fracture unification. Consistent with this 
hypothesis, the RBPjκPrx1 mutant fractures show a relatively nor-
mal periosteal response with robust external callus formation, but 
fail to produce an internal callus and bone union, likely due to the 
depletion of local BMSC populations.
Since our study utilized a constitutively expressed Prx1-Cre 
transgene for the removal of NOTCH signaling in skeletal progeni-
tors throughout skeletal development, it remains a question as to 
precisely when NOTCH signaling is required within skeletal pro-
genitors during fracture repair. It may be that NOTCH signaling is 
required throughout development to maintain a functional pool of 
BMSCs or skeletal progenitors that are ultimately needed follow-
ing skeletal injury for appropriate and complete fracture repair, or 
alternatively, NOTCH signaling may be required within BMSCs or 
skeletal progenitors strictly at the time of fracture repair in order 
to provide the appropriate cues directing bone unification. Parsing 
these differences will require the identification of precisely which 
skeletal progenitors or BMSC populations exhibit functionally 
relevant NOTCH signaling and will also require the development 
or use of appropriate inducible Cre-expressing transgenic mouse 
lines. As we develop these tools, future studies will also examine 
whether these particular NOTCH-deficient fracture nonunions 
can be repaired via the transplantation of appropriate BMSC popu-
lations at appropriate cell concentrations with appropriate cell car-
riers or scaffolds. Further development of these tools and data will 
aid in establishing the critical nature of NOTCH signaling within 
specific BMSC populations that are required for normal fracture 
Figure 6. Loss of NOTCH signaling in fracture callus chondrocytes does not 
result in fracture nonunion. (A) A real-time radiographic comparison of 2 
representative nonstabilized tibia fractures from WT and RBPjκAcanTM mutant 
mice at 0, 14, and 28 dpf, revealed normal fracture repair in RBPjκAcanTM 
mutants. n = 5 mice per genotype per time point. (B) IHC- and ABH/OG-
stained callus sections from RBPjκAcanTM mutants and controls at 10 and 28 
dpf. IHC analyses for RBPjκ shows an extremely efficient removal of RBPjk 
protein in RBPjκAcanTM mutant cartilage calluses. ABH/OG-stained callus sec-
tions indicate no identifiable tissue or cellular alterations in fracture repair 
between WT and RBPjκAcanTM mutant fractures. n = 5 mice per genotype per 
time point. Original magnification, ×20 (IHC); ×5 (ABH/OG).
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mance, all of which are consistent with the clinical 
assessment of human hypertrophic nonunions. 
Furthermore, we observed persistence of the oste-
otomy gap and osseous capping of the intramedul-
lary canal in rigidly stabilized fractures of RBPjκprx1 
mice, which represent endpoint characteristics of 
atrophic nonunions (2, 46). Therefore, these results 
support the concept that BMSCs and potentially 
NOTCH signaling are key cellular and signaling 
participants in the pathogenesis of both hypertro-
phic and atrophic nonunion.
Fracture nonunions are sometimes consid-
ered to be avascular, although recent data suggest 
that no statistically significant change in the medi-
an vessel counts of biopsies from the fracture gap 
of patients with healing fractures, hypertrophic 
nonunions, or atrophic nonunions can be identi-
fied (47). These findings are supported by preclin-
ical models, which have demonstrated the highly 
vascular nature of many nonunions, including 
atrophic nonunions (48, 49). Our study further demonstrates that 
internal callus formation can fail and fracture nonunion can occur, 
even in the presence of a well-vascularized fracture. Collectively, 
these data have extended our understanding of the pathophysiol-
ogy of fracture nonunions and suggest that the fracture nonunions 
characterized here are likely due to the biological impairment of 
local skeletal progenitors at the fracture site or their depletion and 
that NOTCH signaling in particular is a key regulator.
It is of note that children with Alagille syndrome caused by 
JAG1 or NOTCH2 mutations have an especially high risk of low-
er extremity fractures, originally thought to be due to altered 
bone development and metabolism brought on by improper 
calcium, vitamin, and mineral regulation and/or altered osteo-
blast differentiation or function (50). Management of these 
pathological lower extremity fractures in Alagille syndrome 
patients can sometimes be challenging, with reports of recur-
rent fractures in some patients and poor healing outcomes and/
or postfracture deformities in others (50, 51). Therefore, it may 
be important to assess BMSC status and CFU-F frequency in 
the BM of Alagille patients with complicated fracture repair 
scenarios and to consider BMSC or BM aspirate treatments to 
repair and unification and may also provide the basis for develop-
ing cell- and/or molecular-based therapeutics aimed at challenging 
skeletal repair and nonunion scenarios.
Fracture nonunions remain a challenging problem in orthopedic 
surgery. Traditionally, fracture nonunions have been classified as 
hypertrophic and atrophic. Hypertrophic nonunions are often asso-
ciated with inadequate mechanical stabilization; therefore, immobi-
lization alone may be sufficient for treatment. However, for atrophic 
nonunions and a distressing number of cases of hypertrophic non-
unions that do not heal after appropriate surgical intervention, the 
causes have not been explicitly defined, and treatment options are 
limited. Many nonunion animal models are currently available; how-
ever, most of these models rely on creating critical-sized segmental 
defects (42, 43) or removing periosteum and BM (44, 45). These 
models infrequently simulate the clinical human scenario and rarely 
reflect the mechanisms for nonunions occurring in patients. In this 
study, we identified a genetic mouse model for both hypertrophic 
and atrophic nonunions. Specifically, we have demonstrated that 
nonstabilized fractures in RBPjκprx1 mutants display (a) a persistent 
fracture line, (b) no bridging callus formation between cortices, (c) 
fibrosis within the fracture gap, and (d) poor biomechanical perfor-
Figure 7. Insufficient fracture stabilization is not 
absolutely required for the fracture nonunion observed 
in RBPjκPrx1 mutants. (A) A real-time radiographic 
comparison of 1.2-mm osteotomies in WT and RBPjκPrx1 
mutants. n = 6 mice per genotype. (B) Representative 
μCT images of 1.2-mm osteotomies in WT and RBPjκCol1 
mutants at 42 dpf. n = 6 mice per genotype. (C and 
D) Amira analyses of μCT data revealed significantly 
lower bone volume and minimum PMOI in defect zone. 
n = 6 mice per genotype. *P < 0.05 compared with 
WT by 2-tailed, unpaired Student’s t test. Results are 
expressed as mean ± SD. (E) ABH/OG staining and IHC 
for COL3A1 staining on femur fracture sections (1.2-mm 
osteotomy) from WT and RBPjκPrx1 mutants at 42 dpf 
revealed the formation of mesenchymal-like fibrous 
tissue (red arrows) in the 1.2-mm gap. n = 6 mice per 
genotype. Original magnification, ×5.
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lack of union or propensity to fail. Specimens with no bone growth 
for 11 consecutive slices possessed PMOI values of zero, but other 
specimens that were visually nonunified may have possessed non-
zero PMOI values.
After μCT imaging of the fracture calluses, the specimens were 
moistened with PBS and frozen at –20°C until thawed for biomechani-
cal testing as previously described (57). Briefly, specimens were potted 
in polymethyl methacrylate (PMMA) bone cement (DePuyOrthopae-
dics Inc.) in square aluminum tube holders and allowed to rehydrate 
in PBS at room temperature for 1 to 2 hours. Specimens were tested in 
torsion using an EnduraTec TestBench system (200 N.mm torque cell; 
Bose Corp.) at 1°/s until failure. The torque data were plotted against 
the rotational deformation to determine the maximum torque, tor-
sional rigidity, and energy to maximum.
Analysis of mouse tissue sections. From 5 to 7 specimens (tibia or 
femur) in each group obtained at all time points were harvested, 
fixed in 10% neutral buffered formalin for 3 days, decalcified in 
14% EDTA (pH 7.2) for 10 to 14 days, paraffin processed, embed-
ded, and sectioned at a thickness of 3 μm. Sections were stained 
using ABH/OG staining and TRAP in order to analyze the cartilage 
composition and osteoclast formation in the fracture callus tissues. 
IHC stainings for COL3A1 (Abcam, ab7778) and RBPjκ (Cell Signal-
ing) were performed on paraffin sections following the traditional 
antigen retrieval and colorimetric development methodologies. Tis-
sues prepared for frozen sections were fixed in 4% PFA for 2 hours at 
4°C, decalcified with 14% EDTA at 4°C for 10 days, infiltrated with 
gradient sucrose for 3 days, embedded with Tissue-Tek OCT medi-
um, and sectioned at a thickness of 10 μm. LacZ staining and IF for 
PECAM (BD Biosciences, 550274) were performed on frozen sec-
tions. Cartilage area, bone area, mesenchyme area, and OC.S./B.S. 
were quantified on ABH/OG-stained and TRAP-stained sections 
using the Visiopharm Integrator System (Visiopharm).
CFU and molecular assays. BMSCs were isolated from fractured 
mice at 42 dpf or from WT mice at 2 months of age. Femurs and tibi-
ae were removed and BM cells were flushed from the marrow cavity. 
Cells were plated at a density of 1 × 106 cells/well in 6-well tissue cul-
ture plates for 14 days without change of mouse MSC medium (Stem 
Cell Technologies). DAPT/DMSO-treated cultures were grown in 
standard mouse MSC medium for 3 days and then supplemented 
with DAPT (10 μM) or DMSO vehicle control for an additional 14 
days. On either day 14 or 17 after plating, cells were fixed for crystal 
violet and/or ALP staining. Type Ι colonies (CFU-F), as previously 
described (15), and ALP-positive colonies (CFU-OB) were scored. 
RNA was isolated using the RNeasy Mini Kit (QIAGEN) accord-
ing to the manufacturer’s instructions. Real-time quantitative PCR 
(qPCR) was performed to analyze relative gene expression using 
the Bio-Rad CFX Connect Real-Time qPCR System. Gene expres-
sion was normalized to β-actin prior to being normalized to control 
samples. Mouse primers for Hes1, Lepr, Col1a1, Alp, Oc, and β-actin 
are listed in Supplemental Table 1.
Western blot. Bone proteins were extracted from femora and tib-
iae of Prx1-Cre RBPjkfl/fl, Col1a1-Cre; RBPjkfl/fl, and control mice with 
RIPA buffer supplemented with protease inhibitors and phosphatase 
inhibitors (Thermo Scientific, 78440) after BM cells were flushed 
away. Proteins were fractionated in an SDS-PAGE gel, transferred 
to a nitrocellulose membrane, and detected with the RBPjκ antibody 
(Cell Signaling, 5313).
enhance fracture repair. Furthermore, based on our findings, 
it may be relevant to establish the NOTCH signaling status 
within BMSCs and CFU-F frequency in all cases of prolonged 
fracture nonunion, especially when fractures do not heal even 
after appropriate surgical intervention, as it may be that these 
individuals have deficient or defective NOTCH signaling with-
in their clonogenic populations of BMSCs.
Methods
Experimental animals. All mouse strains, including RBPjkfl/fl, Prx1-
Cre, and Col1a1-Cre(2.3 kb), have been described previously (52–54). 
Prx1-Cre RBPjkfl/fl, Prx1-Cre R26RLacZfl/fl, Col1a1-Cre(2.3 kb) RBPjkfl/fl, 
Col1a1-Cre(2.3 kb) R26RLacZfl/fl, and Acan-CreERT2 RBPjkfl/fl mice were 
viable and produced in Mendelian ratios. Mice were fractured at 8 to 
10 weeks of age. Acan-CreERT2 RBPjkfl/fl mice received TM (1 mg/10 g 
body weight) via intraperitoneal injections on 3, 5, 7, and 9 dpf.
Fracture model. Prior to surgery, mice were anesthetized with 
2.5% avertin (15 μl/g body weight) injected intraperitoneally. In the 
nonstabilized tibia fracture model, after the mice were anesthetized, 
an incision along the anterior side of the tibia was made. A transverse 
osteotomy was unilaterally performed at the mid-shaft of the tibia 
with a rotary bone saw. Fractured bones were repositioned with-
out fixation, and the incision was closed. In the rigidly stabilized 
femur-fracture model, the right femur was exposed by a direct lat-
eral approach, and a 4-hole titanium plate was installed across the 
anterolateral surface using 4 titanium screws (55) (RISystem). For 
the 0.66-mm defect, a transverse osteotomy was cut through the 
femoral middiaphysis using a 0.66-mm wire Gigli saw and a cutting 
guide (RISystem). The 1.2-mm osteotomy was created by making 2 
transverse cuts with a 0.22-mm wire Gigli saw and a cutting guide. 
The wound was closed, and the bone was allowed to heal for up to 
6 weeks. Following surgery, mice were kept in cages after recovery 
from anesthesia, allowing free unrestricted weight bearing, and 
buprenorphine was administered subcutaneously (0.1 mg/kg) to 
manage pain every 6 to 12 hours, beginning at the time of sedation, 
for up to 3 days following surgery. Fractures were confirmed immedi-
ately after surgery, and healing of the fractures was monitored week-
ly after fracture under anesthesia using a Faxitron Cabinet X-Ray 
System (Faxitron X-Ray Corp.).
μCT assessment of the mineralized callus and biomechanical torsion 
testing. After careful dissection, repaired tibiae and femurs from days 
14, 28, and 42 were imaged using a μCT system (VivaCT 40, Scanco 
Medical), with an integration time of 300 ms, a current of 145 mA, and 
an energy setting of 55 kV. The threshold was chosen using 2D evalua-
tion of several slices in the transverse anatomic plane so that mineral-
ized callus was identified, but surrounding soft tissue was excluded. 
Quantification for the volumes of the bony calluses was determined as 
previously described using Scanco analysis software (56).
μCT image processing and analysis was also performed using 
Amira software (Amira 5.4.5, FEI Visualization Sciences Group). 
The volume of newly formed bone was measured from the 1.2-mm 
region (114 slices) that corresponded with the initial osteotomy 
after applying a bone mineral density threshold of 435 mg HA/cm3 
to binarize the image. Additionally, the PMOI, which is correlated 
with the bone’s resistance to twisting, was calculated for each slice 
within the 1.2-mm defect region. The mean PMOI of the minimum 
10% of slices was reported, as this is more indicative of the bone’s 
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